oncology – Page 5

Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know

By MedXY 12/13/2025

In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital death across all SACT types.

Hematology-Oncology news Oncology

Clinical Benefit—not Billing Margin—Drives Oncologists’ Treatment Choices in Medicare Cohort

By MedXY 11/22/2025

In a population-based Medicare cohort, oncologists preferentially selected higher-clinical-benefit cancer treatments; provider billing margin was not associated with treatment choice, suggesting price or payment reforms that change margins may not meaningfully alter treatment patterns.

news Oncology

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY 10/25/2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

news Oncology

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY 10/25/2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

news Oncology Respiratory

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

By MedXY 10/25/2025

This article reviews recent clinical trial data showing sevabertinib's efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

Clinical Updates news Oncology Specialties

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

By MedXY 08/06/2025

This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.

news Oncology Specialties

Limited Direct Comparison of Me-Too Oncology Drugs with First-in-Class Agents: Clinical Implications and Regulatory Considerations

By MedXY 07/31/2025

Analysis of FDA approvals from 2009–2020 reveals only 29% of next-in-class oncology drugs underwent head-to-head RCTs against originals, with just 22% showing survival benefits, highlighting a need for incentivized comparative trials.